Concord News Now

As the winter virus season approaches, individuals worldwide search for additional means to protect themselves against respiratory infections, such as COVID-19. In response to the ongoing pandemic, emerging research suggests that nitric oxide nasal spray may offer a novel layer of defense, targeting the precise entry point of the virus into the body. This approach could reduce the risk of infection before, during, and after exposure to COVID-19.

Nasal sprays, a well-established and versatile form of medication delivery, have gained newfound attention for their potential role in bolstering immunity. While this development does not replace the importance of vaccination and other public health measures like mask-wearing, it presents an intriguing avenue for exploration.

Nitric Oxide nasal spray, by design, operates through two fundamental mechanisms in its efforts to mitigate infection. One of these mechanisms involves the creation of a physical barrier. A subset of the nasal spray contains saline solutions and other agents designed to keep the nasal passages moist, facilitating the removal of viruses, bacteria, and other irritants.

The second and more widely recognized method centers around antimicrobial ingredients directly interacting with the virus, impeding its replication. Among these antimicrobial agents, nitric oxide has emerged as a well-studied candidate. Studies conducted in both England and India have demonstrated the effectiveness of a nitric oxide nasal spray in reducing virus levels more rapidly than a placebo in individuals with mild infections.

One such product leading the way in this area is SaNOtize (Enovid), which offers a Nitric Oxide Nasal Spray (NONS). Clinical studies suggest that NONS effectively prevents COVID-19 infection following high-risk exposure. Notably, after confirmed exposure to COVID-19, participants who used NONS experienced an infection rate of 6.4%, compared to 25.6% in the control group (P<0.0001).

These findings build upon previously reported results from a Phase III trial, indicating that the rapid reduction of viral load can prevent infection following exposure to COVID-19. Furthermore, SaNOtize is investigating whether the spray could be effective as a prophylactic measure.

Glenmark’s Phase III clinical trial of SaNOtize’s Nitric Oxide Nasal Spray revealed a remarkable reduction of SARS-CoV-2 viral load by 94% within 24 hours and more than 99% within 48 hours, according to the brand. Nitric oxide nasal spray acts proactively and as a tool to reduce the viral load. It effectively neutralizes viruses in the nasal cavity, a primary entry point for viruses into the respiratory tract, significantly diminishing the viral load in the body. Moreover, it is easy to use and crafted from natural ingredients exclusively.

“SaNOtize Nasal Spray represents a significant advancement in our efforts to combat COVID-19. Backed by compelling scientific research and clinical trials, we have observed notable reductions in viral load. We see it as a promising approach for proactive protection and mitigating viral load among those exposed. The product is distinguished by its safety, natural composition, and user-friendly application, offering a valuable addition to the ongoing battle against respiratory infections,” states the brand spokesperson.

SaNOtize Nasal Spray offers free worldwide shipping and boasts a long shelf life, making it a practical and accessible option for individuals looking to enhance their protection against viral infections.

For more information and to order Enovid Nasal Spray, please visit the official BuyEnov website at https://buyenov.com/

BuyEnov is a prominent medication logistics company headquartered in Israel. Renowned for its swift global services and professional customer support, BuyEnov provides access to high-quality prescription and non-prescription medications. The company has gained recognition for introducing SaNOtize’, Nitric Oxide Nasal Spray (NONS), which offers an additional defense against viral infections.

SaNOtize’s Nitric Oxide Nasal Spray is available as a medical device in Thailand, Singapore, Hong Kong, South Africa, Malaysia, Cambodia, Germany (branded as VirX™), Israel, Indonesia, and Bahrain (branded as enovid™). It is also available in India, with a prescription, under the name FabiSpray. It is not yet approved for sale in Canada or the United States.

VirX™ and enovid™ are identical formulations and have the same active ingredients and mechanisms of action as those nasal therapeutics used in clinical trials. Nothing contained herein should be considered a solicitation, promotion, or advertisement for any drug or medical device including the ones mentioned in this article. Any information on the products contained herein is not intended to provide medical advice, nor should it be used as a substitute for the advice provided by a physician or other healthcare provider.

Enovid, VirX, and FabiSpray are brand names of and owned by SaNotize, a company based in Vancouver, Canada.

Media Contact
Company Name: BuyEnov
Contact Person: Udi
Email: Send Email
Country: Israel
Website: https://buyenov.com/